Valneva (VALN) Competitors $4.53 -0.14 (-3.00%) (As of 09:48 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends VALN vs. TVTX, NTLA, SYRE, PRAX, OCUL, DAWN, SNDX, RCUS, SPRY, and SAVAShould you be buying Valneva stock or one of its competitors? The main competitors of Valneva include Travere Therapeutics (TVTX), Intellia Therapeutics (NTLA), Spyre Therapeutics (SYRE), Praxis Precision Medicines (PRAX), Ocular Therapeutix (OCUL), Day One Biopharmaceuticals (DAWN), Syndax Pharmaceuticals (SNDX), Arcus Biosciences (RCUS), ARS Pharmaceuticals (SPRY), and Cassava Sciences (SAVA). These companies are all part of the "pharmaceutical products" industry. Valneva vs. Travere Therapeutics Intellia Therapeutics Spyre Therapeutics Praxis Precision Medicines Ocular Therapeutix Day One Biopharmaceuticals Syndax Pharmaceuticals Arcus Biosciences ARS Pharmaceuticals Cassava Sciences Valneva (NASDAQ:VALN) and Travere Therapeutics (NASDAQ:TVTX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, community ranking, analyst recommendations, media sentiment, profitability, institutional ownership and risk. Which has better valuation & earnings, VALN or TVTX? Valneva has higher revenue and earnings than Travere Therapeutics. Valneva is trading at a lower price-to-earnings ratio than Travere Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioValneva$165.52M2.22-$109.78M-$0.13-34.85Travere Therapeutics$145.24M9.79-$111.40M-$4.55-4.00 Does the MarketBeat Community prefer VALN or TVTX? Travere Therapeutics received 45 more outperform votes than Valneva when rated by MarketBeat users. However, 60.38% of users gave Valneva an outperform vote while only 57.04% of users gave Travere Therapeutics an outperform vote. CompanyUnderperformOutperformValnevaOutperform Votes3260.38% Underperform Votes2139.62% Travere TherapeuticsOutperform Votes7757.04% Underperform Votes5842.96% Do institutionals and insiders hold more shares of VALN or TVTX? 11.4% of Valneva shares are owned by institutional investors. 14.9% of Valneva shares are owned by insiders. Comparatively, 3.8% of Travere Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has more volatility and risk, VALN or TVTX? Valneva has a beta of 2.17, indicating that its share price is 117% more volatile than the S&P 500. Comparatively, Travere Therapeutics has a beta of 0.7, indicating that its share price is 30% less volatile than the S&P 500. Is VALN or TVTX more profitable? Valneva has a net margin of -4.35% compared to Travere Therapeutics' net margin of -172.75%. Valneva's return on equity of -3.93% beat Travere Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Valneva-4.35% -3.93% -1.42% Travere Therapeutics -172.75%-537.74%-55.65% Do analysts rate VALN or TVTX? Valneva presently has a consensus price target of $18.50, suggesting a potential upside of 308.39%. Travere Therapeutics has a consensus price target of $22.62, suggesting a potential upside of 24.19%. Given Valneva's stronger consensus rating and higher probable upside, analysts plainly believe Valneva is more favorable than Travere Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Valneva 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Travere Therapeutics 0 Sell rating(s) 2 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.85 Does the media prefer VALN or TVTX? In the previous week, Valneva and Valneva both had 4 articles in the media. Travere Therapeutics' average media sentiment score of 0.63 beat Valneva's score of -0.04 indicating that Travere Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Valneva 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Travere Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryValneva beats Travere Therapeutics on 12 of the 17 factors compared between the two stocks. Ad WealthPressBreaking News: Tesla headed to $500…That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla. So to claim your free digital copy today, simply follow this link and enter your email address. Get Valneva News Delivered to You Automatically Sign up to receive the latest news and ratings for VALN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VALN vs. The Competition Export to ExcelMetricValnevaBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$368.06M$2.95B$5.07B$8.80BDividend YieldN/A1.91%4.99%4.07%P/E Ratio-34.8516.8789.5613.60Price / Sales2.22280.301,224.8087.40Price / CashN/A169.3839.4536.27Price / Book1.544.436.976.33Net Income-$109.78M-$41.63M$119.04M$225.93M7 Day Performance-8.48%-5.15%-1.78%-0.96%1 Month Performance-22.16%-6.91%-3.59%1.06%1 Year Performance-62.78%25.64%31.64%26.59% Valneva Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VALNValneva2.2966 of 5 stars$4.53-3.0%$18.50+308.4%-62.1%$368.06M$165.52M-34.85700Gap DownTVTXTravere Therapeutics3.0581 of 5 stars$18.21+2.0%$22.62+24.2%+210.6%$1.42B$145.24M0.00460NTLAIntellia Therapeutics4.5389 of 5 stars$13.80+5.2%$54.94+298.1%-56.7%$1.41B$36.28M-2.58600Analyst ForecastAnalyst RevisionSYRESpyre Therapeutics2.3417 of 5 stars$27.18-1.2%$48.57+78.7%N/A$1.40B$890,000.000.00100PRAXPraxis Precision Medicines1.7647 of 5 stars$73.33-0.5%$146.33+99.6%+299.3%$1.37B$2.45M0.00110OCULOcular Therapeutix3.7464 of 5 stars$8.64-1.6%$16.71+93.5%+273.6%$1.36B$58.44M0.00267DAWNDay One Biopharmaceuticals2.0003 of 5 stars$13.42-1.5%$35.71+166.1%+12.4%$1.35BN/A0.0060Positive NewsSNDXSyndax Pharmaceuticals4.0171 of 5 stars$15.75-1.3%$37.18+136.1%+3.4%$1.34B$139.71M-4.39110Analyst ForecastAnalyst RevisionRCUSArcus Biosciences2.6831 of 5 stars$14.55-0.5%$34.00+133.7%+4.7%$1.33B$117M0.00500SPRYARS Pharmaceuticals2.734 of 5 stars$13.40-1.1%$24.00+79.1%+183.5%$1.30B$30,000.000.0090Analyst RevisionSAVACassava Sciences3.8385 of 5 stars$26.93+3.4%$111.50+314.0%+59.6%$1.30BN/A-18.8830 Related Companies and Tools Related Companies TVTX Alternatives NTLA Alternatives SYRE Alternatives PRAX Alternatives OCUL Alternatives DAWN Alternatives SNDX Alternatives RCUS Alternatives SPRY Alternatives SAVA Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VALN) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Valneva SE Please log in to your account or sign up in order to add this asset to your watchlist. Share Valneva With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VALN Stock Alerts